News
October 15, 2024
Advancing Antibody-Drug Conjugate Therapies: Key Preclinical and Regulatory Strategies for Clinical Success, Upcoming Webinar Hosted by Xtalks
In this free webinar, learn about the complexities of antibody-drug conjugate design, safety concerns and mechanisms of resistance in oncology drug development. Attendees will learn about in vitro and in vivo models that optimize antibody-drug conjugate performance, including essential assays for antibody-drug...
September 4, 2024
Translational Drug Development (TD2) Expands Clinical Trial Services into Europe
SCOTTSDALE, ARIZONA, UNITED STATES, September 4, 2024 /EINPresswire.com/ -- Translational Drug Development (TD2), a leading provider of comprehensive preclinical drug development, translational and clinical trial services, announces the formation of a wholly owned subsidiary in the United Kingdom, TD2...
July 3, 2024
Tara Franks, Chief Operating Officer of TD2, receives 2024 Phoenix Titan 100 Award
Titan CEO and headline sponsor Wipfli LLP are pleased to announce Tara Franks, MBA, Chief Operating Officer of Translational Drug Development (TD2) as a 2024 Phoenix Titan 100. The Titan 100 program recognizes Phoenix’s Top 100 CEOs & C-level executives. They are the area’s most accomplished business leaders in...
June 24, 2024
Atropos Evidence™ Network Grows to Over 300 Million Patients - Becoming Industry’s Largest Federated Healthcare Data Network - and Announces Additional Customer
PALO ALTO, Calif.--(BUSINESS WIRE)--Atropos Health today announced the expansion of the Atropos Evidence Network to include two new partners, adding to the growing number of datasets and use cases for the Atropos Evidence Network including oncology and international. The company additionally announced a new...
April 04, 2024
SCRS Welcomes TD2 as Global Impact and Oncology Spirit Partner
April 4, 2024 – The Society for Clinical Research Sites (SCRS) is pleased to welcome Translational Drug Development (TD2) as an SCRS Global Impact Partner and Oncology Spirit Partner. TD2 is a leading provider of comprehensive preclinical drug development, translational and clinical trial services based in...
April 03, 2024
TD2 to Present Precision Preclinical Applications for Glioblastoma and Non-Small Cell Lung Cancer at AACR Annual Meeting
SCOTTSDALE, ARIZONA, UNITED STATES, April 3, 2024 /EINPresswire.com/ -- Translational Drug Development (TD2), a precision oncology contract research organization (CRO), announces the presentation of their preclinical results of three novel studies targeting non-small cell lung cancer and glioblastoma at the...
February 01, 2024
TD2 Expands Preclinical and Clinical Services by Acquiring Flow Contract Site Laboratory (FCSL)
SCOTTSDALE, ARIZONA, USA, February 1, 2024 /EINPresswire.com/ -- Translational Drug Development (TD2), a leading provider of comprehensive preclinical drug development, translational and clinical trial services, is pleased to announce its acquisition of Flow Contract Site Laboratory (FCSL) located in Bothell,...
December 05, 2023
TD2 to Highlight Development of a Dual-Specific Inhibitor for Treatment of Primary Myelofibrosis at ASH Annual Meeting
SCOTTSDALE, ARIZONA, USA, December 5, 2023 /EINPresswire.com/ Translational Drug Development (TD2), a precision oncology contract research organization (CRO), announces the presentation of preclinical results of RR-1752, a targeted inhibitor of ROCK/AURK, for primary myelofibrosis at the American Society of...
August 17, 2023
Qualigen Therapeutics Partners with TD2 for Phase 1 Clinical Development of QN-302 for the Treatment of Advanced or Metastatic Solid Tumors
CARLSBAD, Calif., Aug. 17, 2023 (GLOBE NEWSWIRE) Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, announced today it is partnering with Translational Drug Development (TD2)...
May 17, 2023
Tara Franks, Chief Operating Officer of TD2, recognized as a 2023 Phoenix Titan 100
SCOTTSDALE, ARIZONA, UNITED STATES, May 17, 2023 / EINPresswire.com/ — Titan CEO and headline sponsor Wipfli LLP are pleased to announce Tara Franks, Chief Operating Officer of Translational Drug Development (TD2), as a 2023 Phoenix Titan 100. The Titan 100 program recognizes Phoenix’s Top 100 CEO’s & C-level...
April 11, 2023
TD2 to Highlight the Development of a Novel Metabolomic Cancer Model at the AACR Annual Meeting 2023
SCOTTSDALE, ARIZONA, UNITED STATES, April 11, 2023/EINPresswire.com/ — Translational Drug Development (TD2), a precision oncology contract research organization (CRO), announces the presentation of their preclinical development of a novel Diet-Induced Obesity Model for antitumor, proteomic, and metabolomic...
October 5, 2022
SELLAS Life Sciences’ Highly Selective CDK9 Inhibitor, GFH009, Demonstrates Cancer Cell Growth Inhibition in Preclinical In Vitro Model of Neuroendocrine Prostate Cancer Cell Line
The respected Medical Oncology leader brings extensive experience as TD2 continues its strategic growth.
August 8, 2022
SELLAS Life Sciences’ GFH009 Demonstrates Cancer Cell Growth Inhibition in Preclinical In Vitro Studies in Solid Cancer and Acute Myeloid Leukemia Cell Lines
NEW YORK, Aug. 09, 2022 (GLOBE NEWSWIRE) – SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced results from preclinical in vitro studies...
May 12, 2022
Genzada Pharmaceuticals Opens Phase 1B Metastatic Breast Cancer Trial
HUTCHINSON, Kan. – May 12, 2022 – Genzada Pharmaceuticals USA Inc. (Genzada), a subsidiary of Ionics Pharmaceuticals SA, announced today the official opening of a Phase 1B clinical trial for the oral therapeutic GZ17-6.02 (6.02) in combination with capecitabine in patients with metastatic breast cancer.
April 5, 2022
TD2 to Highlight Preclinical Progress of Two Novel HDAC Inhibitors at AACR Annual Meeting
SCOTTSDALE, ARIZONA, UNITED STATES, April 5, 2022 /EINPresswire.com/ — Translational Drug Development (TD2), a precision oncology contract research organization (CRO), announces the presentation of the preclinical results of two novel, targeted epigenetic inhibitors at the American Association for Cancer Research...
March 30, 2022
Qualigen Therapeutics Engages TD2 as Contract Research Organization for Preclinical Development of QN-302
CARLSBAD, Calif., March 30, 2022 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces it has appointed...
October 14, 2021
TD2 Partners with Medidata to Enhance its Clinical Operations and Accelerate Clinical Trials
Medidata, a Dassault Systèmes company, today announced that Translational Drug Development (TD2), a precision oncology contract research organization (CRO), has signed an agreement to adopt Medidata’s Rave CTMS (Clinical Trial Management System) and eTMF (electronic Trial Master File) solutions. Rave CTMS and...
September 16, 2021
TD2 and Deep Lens Partner to Enable Diversity, Access and Faster Clinical Trial Enrollment for Community Oncology Practices
Key Partnership Will Connect Patients with Precision Oncology Clinical Trials and Novel Therapies, Accelerating Access to Promising Treatments Translational Drug Development (TD2), a leading precision oncology contract research organization (CRO), and Deep Lens have announced a strategic partnership that will...
November 24, 2020
Laidlaw Venture Partners Portfolio Company Voltron Therapeutics Enters into Strategic Development Agreement
The Companies Plan to Focus On Voltron’s VaxCelerate Vaccine Platform’s Effectiveness and Utility in a Variety of Tumor Settings Laidlaw Venture Partners (“LVP”), the venture capital arm of Laidlaw & Company (UK) Ltd., today announced a strategic development agreement with Translational Drug Development (TD2), a...
October 29, 2020
TD2 and VieCure Partner to Bring Best-in-Class Cancer Medicines and Access to Precision Oncology Clinical Trials to Patients in Community Oncology Practices
Partnership Will Accelerate the Awareness and Adoption of Precision Oncology in Private Practices and Community Oncology Cancer Centers in the United States Translational Drug Development (TD2), a precision oncology contract research organization (CRO), and VieCure have announced a strategic partnership that will...
September 28, 2020
Applied Clinical Trials: Small Biopharma and CROs: Seeking Stronger Synergies
Many emerging biopharmaceutical companies hire contract research organizations (CROs) because of limited staffing and regulatory experience to help them navigate the regulatory pathway. CROs are instrumental in helping these biopharma overcome obstacles such as clinical trial timeline delays, out-of-scope change...
July 16, 2020
Ready to Make an Impact? Join Our Team.
One look inside our company and it’s clear – drug development is our passion and we are dedicated to bringing the most successful oncology treatments to patients as quickly as possible. With a team of experts that bring their own unique knowledge, insight and experience to the table, TD2 is looking for new...
June 16, 2020
PM360: COVID-19’s Long-Lasting Impact on Clinical Trials
With COVID-19 impacting the conduct of clinical trials, a lot of discussion has been around what changes have allowed trials to continue recruitment. Protocol amendments and the use of technology are just a couple examples of trial aspects that have been drastically impacted by the pandemic, and are expected to...
June 4, 2020
RCT Acquires Translational Drug Development, LLC
Research Corporation Technologies, Inc. (RCT) announced today that it has acquired and invested growth capital into Translational Drug Development (TD2), the leading fully integrated precision oncology medicine development organization. TD2 provides end-to-end solutions, including translational preclinical...
March 25, 2020
TD2 Business Continuity during COVID-19
Our team remains committed to serving our clients and bringing cancer treatments to patients as quickly and safely as possible during this unique time. Based on the recommendations from “FDA’s Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Pandemic”, as well as the US Center for...
April 10, 2019
Genzada Pharmaceuticals Doses First Patient
First cancer patient receives dose of super-enhancer inhibitor GZ17-6.02, an advanced cancer drug from Genzada Pharmaceuticals. Genzada Pharmaceuticals USA Inc.(Genzada), a subsidiary of Ionics Life Sciences Limited, announced today that the first patient enrolled in its Phase 1 clinical trial for the oral...
March 20, 2019
First Cancer Patient Receives Dose of Super-Enhancer Inhibitor GZ17-6.02, an Advanced Cancer Drug from Genzada Pharmaceuticals, at HonorHealth Research Institute
Genzada Pharmaceuticals USA Inc. (Genzada), a subsidiary of Ionics Life Sciences Limited, announced today that the first patient enrolled in its Phase 1 clinical trial for the oral therapeutic GZ17-6.02 received the first dose this week at HonorHealth Research Institute in Scottsdale, Ariz. Genzada’s GZ17-6.02...
August 2, 2018
Outsourcing-Pharma: Targeting special patient populations with the help of AI
One of the biggest challenges of clinical trials is identifying the specific patient populations. This is a factor that has become even more critical with the rise of highly targeted oncology medicines. The solution: Artificial intelligence (AI) techniques which unify structured and unstructured clinical patient...
July 27, 2018
Applied Clinical Trials: When is it Time to Kill Your Drug?
It can be hard for drug makers to pull the plug on a drug in development, even when all signs indicate they should – resulting in many drugs getting past the preclinical floodgates, only to fail. The mistake: Not having a clinical strategy from the get-go.
July 18, 2018
TD2 Receives Three-Year Renewal of AAALAC Accreditation
We’re pleased to announce that our preclinical laboratory has again earned a Full Accreditation from AAALAC International Council.
July 17, 2018
TD2 Selected to Conduct IO Preclinical Program for Atossa Genetics
Atossa Genetics Inc. (ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that it is advancing its intraductal microcatheter immunotherapy program with pre-clinical...
June 22, 2018
Stephen Gately Discusses Precision Medicine in Applied Clinical Trials
Cancer is now classified not only by the organ of origin, but by genomic and proteomic profiling.
June 5, 2018
Your Guide to a Smart Clinical Strategy
Drug research has advanced in remarkable ways, but it’s still about the basics: ensuring safety, efficacy and compliance. That trio is no easy feat, but without a strong clinical strategy, even the most promising, safe and compliant drug can fail. Get your research in better strategic shape with this quick-start...
May 25, 2018
TD2 Supports The Side-Out Foundation in Clinical Trial Exploring the Treatment of Metastatic Breast Cancers Based on Multi-Omic Profiling
Results announced at the annual ASCO meeting on June 2, 2018
April 25, 2018
6 Signs You Need a New CRO for Your Preclinical Research
You have goals for every project, and your CRO should be as committed to those goals as you are. But if things take too long to get done, don’t rush to flip the kill switch on your project. It might be time to switch CROs instead. Learn to spot these six signs your preclinical work needs a new CRO:
April 17, 2018
TD2 Supports CRISPR Therapeutics for Solid Cancer Study Involving CAR T Cells
Translational Drug Development (TD2)—an oncology-specialty CRO that guides medicines through the preclinical, regulatory and clinical trial processes—conducted preclinical trials over the past six months that examined the effectiveness of a durable, off-the-shelf anti-CD70 CAR T cell against a human clear cell...
March 1, 2018
Finding and Selecting the Right Tumor Models
As an oncology researcher, it’s essential to have access to molecularly defined models that recapitulate tumor-promoting cancer drivers. But which models are best, and how can you ensure you’re selecting the right ones with the right contexts for preclinical success? For starters, your model selection should...
October 23, 2017
Oral Formulation of Minnelide is Dosed For the First Time in Patients with Advanced Cancer
Minneamrita Announces FDA Clearance of Investigational New Drug (IND) Application and Initiation of a Phase I Clinical Trial of an Oral Formulation of Minnelide in Patients with Advanced Cancer. Minneamrita today announced that an Investigational New Drug (IND) application to the U.S. Food and Drug Administration...
May 31, 2017
TD2 and Deep 6 AI Announce Partnership to Accelerate Oncology Clinical Trial Recruitment
Artificial intelligence used to identify potential clinical trial participants in minutes. Translational Drug Development (TD2) and Deep 6 AI announced today a formal agreement to work together in the fields of oncology and fibrosis to rapidly match eligible patients with appropriate clinical trials. The...
March 23, 2017
Merrimack and TD2 Work Together on the Phase 1 Study of MM-310
Merrimack Initiates Phase 1 Study of MM-310 in Solid Tumors. Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced the enrollment of its first patient in a Phase 1 study of MM-310 in solid tumors. MM-310 is an antibody-directed nanotherapeutic (ADN) that encapsulates a novel taxane and targets the EphA2...
March 18, 2017
NCI and Investigational Drugs: What Is the Role?
The role of the National Cancer Institute (NCI) with respect to investigational drugs is that of a sponsor. NCI acts as a sponsor to many, but not all, investigational drugs moving through the FDA approval process. NCI acts as a gatekeeper for all the physicians who are participating in clinical trials for the...
March 4, 2017
Are All Investigational Drugs Available Through an Expanded Access or Special Exemption Mechanism?
When it comes to oncology drugs, not all investigational drugs are available through an expanded access or special exemption mechanism. The main factors affecting an investigational drug’s availability outside of a clinical drug investigation include:
February 18, 2017
Are There Other Ways to Get Investigational Drugs?
Although the most common way for patients to get access to an investigational new drug is through a clinical trial, there are other avenues that physicians and patients can pursue.
January 27, 2017
Are Cancer Clinical Trials Just for Advanced Cancer?
Most people wanting to participate in cancer clinical trials are people suffering advanced cancer. Having depleted treatment options that failed to stop the progression of their cancer, these patients choose to engage in clinical trials offering new and promising anti-cancer treatments. However, many cancer...
December 16, 2016
What Is the Difference Between Standard Therapy and Experimental Therapy in a Cancer Clinical Trial?
The U.S. Food and Drug Administration’s Center for Drug Evaluation and Research is responsible for ensuring all drugs marketed in the U.S. are effective and safe for human use. However, the CDER does not necessarily test drugs, but conducts limited research regarding the quality, effectiveness and safety of drugs.
December 2, 2016
What Is Standard Therapy in Cancer Treatment?
Standard therapies for treating cancer include surgery, radiation therapy and chemotherapy, depending on the part of the body affected and stage at which the cancer is diagnosed. Solid tumors respond well to surgery if they are contained or localized. Non-solid cancer, such as leukemia, requires radiation,...
November 18, 2016
What Is a Randomized Cancer Clinical Trial?
All clinical trials progress through levels—Phase I, Phase II and Phase III. Phase I of a clinical trial involves studying the new drug or treatment to discover a safe dose amount. Evaluation of the drug’s safety at different doses determines whether more testing is needed. People participating in Phase I cancer...
November 16, 2016
TD2 Supports the Successful IND Filing for Genzada Pharmaceuticals
Genzada Pharmaceuticals announces FDA clearance of IND application and launch of phase I human clinical trial for middle eastern-derived advanced cancer drug. First-in-Human Trial Launched for Super-Enhancer Inhibitor GZ17-6.02 Genzada Pharmaceuticals USA Inc., a subsidiary of Ionics Life Sciences Limited...
November 4, 2016
Why Are Randomized Cancer Clinical Trials Important in Developing New Treatments for Cancer?
Used extensively in biological experiments and human clinical trials, randomization prevents both accidental and selection bias by eliminating sources of bias and producing comparable groups. Randomizing clinical trials also allows utilization of probability theory for expressing the likeliness of chance events...
October 21, 2016
Where Do Cancer Clinical Trials Take Place?
Conducted in hospitals, veterans’ medical centers, university hospitals, medical clinics, cancer centers or physicians’ offices, cancer clinical trials test drugs, blood products, medical devices, biologics and other therapies that have the potential for treating cancer. Locations of cancer clinical trials may...
September 15, 2016
What Is an Investigational Drug?
The development of a new drug is a long and involved process that requires months, if not years, of lab work and testing. However, if results are promising, the drug company or a sponsor can send a request, formally called an Investigational New Drug application, to the US Food and Drug Administration (FDA),...
July 15, 2016
TD2 to Present at the Upcoming 4th Annual Tumor Models in Boston
TD2’s VP of Nonclinical Operations, Paul Gonzales, will be presenting at the upcoming 4th Annual Tumor Models – Boston (www.tumor-models.com) on Wednesday, July 20th. The topic of the presentation is The Role of the Gut Microbiome on the Anti-Tumor Response of Immune Checkpoint Inhibitors in a Syngeneic Murine...
April 28, 2016
TD2 Works Closely with ZIOPHARM Oncology to Conduct a Preclinical Study Being Presented at the Upcoming ASGCT Meeting in Washington, DC
Below is the abstract seelcted for presentation at the upcoming American Society of Gene & Cell Therapy 19th Annual Meeting:
April 20, 2015
TD2 and Navigating Cancer Partner to Bring Patient-Reported Outcomes to Clinical Trials Through a Cutting-Edge Mobile Application
Leading patient engagement and mobile care management solution and precision oncology CRO partner to revolutionize patient engagement in clinical trials Scottsdale, AZ and Seattle, WA – April 20, 2015 — TD2, the precision oncology CRO, and Navigating Cancer, the leading web-based patient care and engagement...
April 20, 2015
Paradigm and TD2 Announce Strategic Partnership For Tumor Profiling Service
Collaboration to provide expanded use of Paradigm Cancer Diagnostic (PCDx™) service by oncologists across large oncology network SCOTTSDALE, AZ and ANN ARBOR, MI Monday, April 20, 2015 — Paradigm and Translational Drug Development (TD2) today announced a partnership under which Paradigm will provide their PCDx...
September 10, 2014
Responsibility for Pancreatic Cancer Research Team Moves to Seattle Non-Profit Institution
Responsibility for Pancreatic Cancer Research Team Moves to Seattle Non-Profit Institution
June 23, 2014
Inform Genomics and Translational Drug Development (TD2) Announce Strategic Collaboration
TD2 and Inform Genomics Announce Strategic Partnership
April 3, 2014
MPI and TD2 Join in Strategic Collaboration to Provide Drug Developers a Unique Multi Biomarker Direct Path to Drug Approval
MPI and TD2 Join in Strategic Collaboration to Provide Drug Developers a Unique Multi Biomarker Direct Path to Drug Approval
April 1, 2014
Nuvilex Selects Translational Drug Development (TD2) to Advance Treatment for Pancreatic Cancer
Nuvilex Retains TD2 to Conduct Preclinical and Clinical Studies
April 1, 2014
Forma Therapeutics makes deal with Celgene potentially worth $600M
Forma Therapeutics makes deal with Celgene worth $600M
March 10, 2014
Dr. Daniel D. Von Hoff named one of ASCO’s 50 Oncology Luminaries
Dr. Von Hoff’s research led to development of numerous therapeutic agents, and improved patient care. In association with its 50th anniversary, the American Society of Clinical Oncology (ASCO) has named Dr. Daniel D. Von Hoff one of ASCO’s 50 Oncology Luminaries, celebrating 50 doctors who over the past...
December 18, 2013
Translational Drug Development (TD2) attracts Dallas partner
ORIX USA brings investment dollars that will enable TD2 to expand; help grow Arizona’s biomedical economy
September 15, 2013
FORMA THERAPEUTICS ANNOUNCES ADVANCEMENT OF TUMOR METABOLISM COLLABORATION WITH JANSSEN
Ongoing Collaboration Advances as FORMA Therapeutics Receives Licensing Payment and Additional Research Funding
September 12, 2013
First-in-Human Thunder God Vine Trial-Minnelide
TGen and Scottsdale Healthcare launch Phase I ‘Thunder God vine’ trial for cancer
September 6, 2013
FDA approves drug tested by Scottsdale Healthcare and TGen
Abraxane now part of standard-of-care for patients with advanced pancreatic cancer, following studies at the Virginia G. Piper Cancer Center at Scottsdale Healthcare
July 17, 2013
TGen-TD2-Scottsdale Healthcare breast cancer pilot study
TGen-TD2-Scottsdale Healthcare breast cancer pilot study shows value of molecular profiling and proteomic mapping Patients benefit from treatments tailored specifically for their tumor types; stage set for larger study
June 14, 2013
TD2 helps SideOut Foundation with the conduct of their trial
TD2 helps SideOut Foundation with the conduct of their trial Article written by: Michele McDonald at George Mason University
May 30, 2013
Pancreatic Cancer Research Team (PCRT) celebrates its 10-year anniversary of delivering new treatments for patients with pancreatic cancer
Ten Years after its founding, the Pancreatic Cancer Research Team (PCRT) is announcing the positive results of a large Phase III clinical trial involving more than 800 patients. PCRT is celebrating its 10th anniversary of accelerating new and effective medicines to patients with pancreatic cancer.
April 29, 2013
TD2 is the development partner for the FORMA/Celgene partnership
WATERTOWN, Mass. – April 29, 2013 – FORMA Therapeutics Holdings, LLC (FORMA) today announced a strategic collaboration agreement with Celgene Corporation under which FORMA and Celgene will discover, develop and commercialize drug candidates to regulate protein homeostasis targets.
June 18, 2012
Forma Therapeutics teams with TD2
June 18, 2012 – FORMA Therapeutics and TGen Drug Development (TD2) today announced an agreement to jointly develop transformative cancer therapies, leveraging the synergistic capabilities of both organizations.
June 5, 2012
Flagship Biosciences finds Arizona a great home for serving pathology digitally
While most of Flagship’s customers are at biotech and pharma locations around the world, there has been some strong collaborations formed with Arizona biotech firms. “The collaboration spirit in Arizonais remarkable” said Steve Potts. “the amount of additional business that Arizona groups like TGEN generate for...
May 31, 2012
CytRx Initiates Phase 2 Clinical Trial with INNO-206 in Pancreatic Cancer
Daniel Von Hoff, M.D., Physician-in-Chief and Distinguished Professor at the Translational Genomics Research Institute (TGEN) in Phoenix will serve as the clinical trial’s principal investigator while TGen’s subsidiary, TGen Drug Development, manages this Phase 2 clinical trial on behalf of CytRx. Dr. Von Hoff...
August 25, 2011
TGen Drug Development (TD2) partnership with Imaging Endpoints provides comprehensive clinical trial services for drug developers
TGen Drug Development (TD2) and Imaging Endpoints have teamed up to enable the rapid development of anti-cancer drugs and deliver them faster to patients in need, the companies announced today.
January 16, 2010
BioSpace: What Does 2020 Have in Store for Life Sciences?
While the past decade presented us with significant biotech and pharmaceutical advances, the future of the industry looks even more promising due to a few key focus areas that are predicted to lead the market in 2020, including oncology, cell and gene therapies, and real-world evidence.
